<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39364598</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>40</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill</ISOAbbreviation></Journal><ArticleTitle>Attribution of invasive group A streptococcal infections (iGAS) to predisposing viral infections, the Netherlands, 2010 to 2023.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2300739</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2807/1560-7917.ES.2024.29.40.2300739</ELocationID><Abstract><AbstractText>BackgroundAfter most COVID-19 pandemic control measures were lifted in 2022, many infectious diseases re-emerged. An increase in invasive group A streptococcal (iGAS) infections among adults and young children was reported by several countries. Viral infections including influenza and varicella, known risk factors for iGAS infection, also increased.AimTo estimate the proportion of GAS skin and soft tissue infections (SSTI) and pneumonia/sepsis in children (≤ 5 years) attributable to varicella, and the proportion of GAS pneumonia/sepsis in children and adults attributable to potentially predisposing respiratory viruses influenza A and B, RSV, hMPV and SARS-CoV-2 in the Netherlands.MethodsWe performed time series regression using weekly data on respiratory viruses, varicella and non-invasive GAS infections and GAS isolates cultured from blood, lower airways, skin, pus and wounds, from January 2010 to March 2023.ResultsIn 2010-19, 50% (95% CI: 36-64) of GAS SSTI in children were attributable to varicella. Between January 2022 and March 2023, 34% (95% CI: 24-43) of GAS SSTI cases were attributable to varicella. Of iGAS pneumonia/sepsis between January 2022 and March 2023, 34% (95% CI: 20-49) and 25% (95% CI: 18-32) was attributable to respiratory virus infections in children and adults, respectively, with the largest contributor (17%) being influenza A.ConclusionsPredisposing viral infections likely contributed to, but cannot fully explain, the observed iGAS increase among children and adults in 2022-23 in the Netherlands. Public health measures to control viral infections, such as vaccination against varicella or influenza, might reduce the iGAS disease burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Gier</LastName><ForeName>Brechje</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Kassteele</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Asten</LastName><ForeName>Liselotte</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schoffelen</LastName><ForeName>Annelot F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ISIS-AR study group</CollectiveName><AffiliationInfo><Affiliation>The members of the ISIS-AR study group are listed under Collaborators.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooiveld</LastName><ForeName>Mariette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nivel, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Te Wierik</LastName><ForeName>Margreet Jm</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Sorge</LastName><ForeName>Nina M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center location AMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam University Medical Center location AMC, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Melker</LastName><ForeName>Hester E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Members of the ISIS-AR study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013290" MajorTopicYN="Y">Streptococcal Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013297" MajorTopicYN="Y">Streptococcus pyogenes</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002644" MajorTopicYN="N">Chickenpox</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018461" MajorTopicYN="N">Soft Tissue Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="N">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Streptococcus pyogenes</Keyword><Keyword MajorTopicYN="N">Varicella</Keyword><Keyword MajorTopicYN="N">timeseries analysis</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> NMvS declares fee for service and consultancy fees from MSD and GSK outside the submitted work directly paid to the institution. NMvS declares royalties related to a patent (WO 2013/020090 A3) on vaccine development against Streptococcus pyogenes (Vaxcyte; Licensee: University of California San Diego with NMvS as co-inventor). NMvS is a member of the science advisory board for the ItsME foundation (unpaid) and Rapua te me ngaro ka tau project (Protection of Whãnua against Strep A (POWAS); paid to institution). The other authors have nothing to declare.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Cohen Stuart</LastName><ForeName>Jwt</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melles</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alzubaidy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scholing</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuil</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blaauw</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altorf van der Kuil</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bierman</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Greeff</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Groenendijk</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hertroys</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monen</LastName><ForeName>Jcm</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Notermans</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Reek</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneeberger-van der Linden</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velthuis</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wielders</LastName><ForeName>Cch</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Wit</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zoetigheid</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Bijllaardt</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kraan</LastName><ForeName>E M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haeseker</LastName><ForeName>M B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>da Silva</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Jong</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maraha</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Griethuysen</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wintermans</LastName><ForeName>B B</ForeName><Initials>BB</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Trijp</LastName><ForeName>Mjca</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muller</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bathoorn</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lokate</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinnige</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melles</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plantinga</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Renders</LastName><ForeName>N H</ForeName><Initials>NH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorigo-Zetsma</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakker</LastName><ForeName>L J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waar</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Beek</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leversteijn-van Hall</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Mens</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaftenaar</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nabuurs-Franssen</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maat</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sturm</LastName><ForeName>Pdj</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diederen</LastName><ForeName>Bmw</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bode</LastName><ForeName>Lgm</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ong</LastName><ForeName>Dsy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Rijn</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dinant</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>den Reijer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dam</LastName><ForeName>D W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Brauwer</LastName><ForeName>Eigb</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bentvelsen</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buiting</LastName><ForeName>Agm</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vlek</LastName><ForeName>Alm</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Graaf</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troelstra</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jansz</LastName><ForeName>A R</ForeName><Initials>AR</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Meer</LastName><ForeName>Mpa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Vries</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Machiels</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364598</ArticleId><ArticleId IdType="pmc">PMC11451131</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.40.2300739</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Gier B, Marchal N, de Beer-Schuurman I, Te Wierik M, Hooiveld M, de Melker HE, et al. Increase in invasive group A streptococcal (Streptococcus pyogenes) infections (iGAS) in young children in the Netherlands, 2022. Euro Surveill. 2023;28(1):2200941. 10.2807/1560-7917.ES.2023.28.1.2200941</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.1.2200941</ArticleId><ArticleId IdType="pmc">PMC9817208</ArticleId><ArticleId IdType="pubmed">36695447</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). Increase in invasive group A streptococcal infections among children in Europe, including fatalities. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/news-events/increase-invasive-group-streptococcal-infections-among-children-europe-including
</Citation></Reference><Reference><Citation>Guy R, Henderson KL, Coelho J, Hughes H, Mason EL, Gerver SM, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. Euro Surveill. 2023;28(1):2200942. 10.2807/1560-7917.ES.2023.28.1.2200942</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.1.2200942</ArticleId><ArticleId IdType="pmc">PMC9817207</ArticleId><ArticleId IdType="pubmed">36695450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassoued Y, Assad Z, Ouldali N, Caseris M, Mariani P, Birgy A, et al. Unexpected increase in invasive group A streptococcal infections in children after respiratory viruses outbreak in France: a 15-year time-series analysis. Open Forum Infect Dis. 2023;10(5):ofad188. 10.1093/ofid/ofad188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad188</ArticleId><ArticleId IdType="pmc">PMC10167988</ArticleId><ArticleId IdType="pubmed">37180594</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia C, Bajanca-Lavado MP, Mamede R, Araújo Carvalho A, Rodrigues F, Melo-Cristino J, et al. Sustained increase of paediatric invasive Streptococcus pyogenes infections dominated by M1UK and diverse emm12 isolates, Portugal, September 2022 to May 2023. Euro Surveill. 2023;28(36):2300427. 10.2807/1560-7917.ES.2023.28.36.2300427</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.36.2300427</ArticleId><ArticleId IdType="pmc">PMC10486195</ArticleId><ArticleId IdType="pubmed">37676143</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobo-Vazquez E, Aguilera-Alonso D, Carrasco-Colom J, Calvo C, Saavedra-Lozano J, PedGAS-net Working Group . Increasing incidence and severity of invasive Group A streptococcal disease in Spanish children in 2019-2022. Lancet Reg Health Eur. 2023;27:100597. 10.1016/j.lanepe.2023.100597</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100597</ArticleId><ArticleId IdType="pmc">PMC9989682</ArticleId><ArticleId IdType="pubmed">36895202</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U, Hartling UB, Munkstrup C, Nielsen AB, Dungu KHS, Schmidt LS, et al. Invasive group A streptococcal infections in children and adolescents in Denmark during 2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre, population-based cohort study. Lancet Child Adolesc Health. 2024;8(2):112-21. 10.1016/S2352-4642(23)00295-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(23)00295-X</ArticleId><ArticleId IdType="pubmed">38103567</ArticleId></ArticleIdList></Reference><Reference><Citation>Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics. 2000;105(5):E60. 10.1542/peds.105.5.e60</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.105.5.e60</ArticleId><ArticleId IdType="pubmed">10799624</ArticleId></ArticleIdList></Reference><Reference><Citation>Imöhl M, van der Linden M, Reinert RR, Ritter K. Invasive group A streptococcal disease and association with varicella in Germany, 1996-2009. FEMS Immunol Med Microbiol. 2011;62(1):101-9. 10.1111/j.1574-695X.2011.00788.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-695X.2011.00788.x</ArticleId><ArticleId IdType="pubmed">21314732</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera AL, Huber VC, Chaussee MS. The association between invasive group A streptococcal diseases and viral respiratory tract infections. Front Microbiol. 2016;7:342. 10.3389/fmicb.2016.00342</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2016.00342</ArticleId><ArticleId IdType="pmc">PMC4800185</ArticleId><ArticleId IdType="pubmed">27047460</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gier B, Vlaminckx BJM, Woudt SHS, van Sorge NM, van Asten L. Associations between common respiratory viruses and invasive group A streptococcal infection: A time-series analysis. Influenza Other Respir Viruses. 2019;13(5):453-8. 10.1111/irv.12658</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12658</ArticleId><ArticleId IdType="pmc">PMC6692538</ArticleId><ArticleId IdType="pubmed">31237087</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, Vermont CL, Quaak MSW, Janson JA, et al. Increase in invasive group A streptococcal infections in children in the Netherlands, a survey among 7 hospitals in 2022. Pediatr Infect Dis J. 2023;42(4):e122-4. 10.1097/INF.0000000000003810</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003810</ArticleId><ArticleId IdType="pubmed">36728741</ArticleId></ArticleIdList></Reference><Reference><Citation>Altorf-van der Kuil W, Schoffelen AF, de Greeff SC, Thijsen SF, Alblas HJ, Notermans DW, et al. National laboratory-based surveillance system for antimicrobial resistance: a successful tool to support the control of antimicrobial resistance in the Netherlands. Euro Surveill. 2017;22(46):17-00062. 10.2807/1560-7917.ES.2017.22.46.17-00062</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.46.17-00062</ArticleId><ArticleId IdType="pmc">PMC5718398</ArticleId><ArticleId IdType="pubmed">29162208</ArticleId></ArticleIdList></Reference><Reference><Citation>Nivel. Actuele Weekcijfers Aandoeningen- Surveillance. Utrecht: Nivel; 2023. Available from: https://www.nivel.nl/nl/zorg-en-ziekte-in-cijfers/actuele-cijfers-ziekten-per-week
</Citation></Reference><Reference><Citation>World Health Organization (WHO). International Classification of Primary Care, 2nd edition (ICPC-2). Geneva: WHO; 2024. Available from: https://www.who.int/standards/classifications/other-classifications/international-classification-of-primary-care
</Citation></Reference><Reference><Citation>De Gier B, Nijsten DRE, Duijster JW, Hahne SJM. Virological surveillance in the Netherlands- Virological weekly reports. State of Infectious Diseases in the Netherlands, 2016. RIVM Report 2017-0029/2017. Bilthoven: RIVM; 2017. Available from: https://www.rivm.nl/bibliotheek/rapporten/2017-0029.pdf
</Citation></Reference><Reference><Citation>van Boven M, Hetebrij WA, Swart A, Nagelkerke E, van der Beek RF, Stouten S, et al. Patterns of SARS-CoV-2 circulation revealed by a nationwide sewage surveillance programme, the Netherlands, August 2020 to February 2022. Euro Surveill. 2023;28(25):2200700. 10.2807/1560-7917.ES.2023.28.25.2200700</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.25.2200700</ArticleId><ArticleId IdType="pmc">PMC10288829</ArticleId><ArticleId IdType="pubmed">37347416</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilers PHC, Marx BD. Flexible smoothing with B-splines and penalties. Stat Sci. 1996;11(2):89-121. 10.1214/ss/1038425655</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/ss/1038425655</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheipl F. spikeSlabGAM: bayesian variable selection, model choice and regularization for generalized additive mixed models in R. J Stat Softw. 2011;43(14):1-24. 10.18637/jss.v043.i14</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v043.i14</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparrini A. Distributed Lag Linear and Non-Linear Models in R: The Package dlnm. J Stat Softw. 2011;43(8):1-20. 10.18637/jss.v043.i08</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v043.i08</ArticleId><ArticleId IdType="pmc">PMC3191524</ArticleId><ArticleId IdType="pubmed">22003319</ArticleId></ArticleIdList></Reference><Reference><Citation>R Foundation for Statistical Computing. R: A language and environment for statistical computing. Vienna: R Core Team; 2022. Available from: https://www.R-project.org
</Citation></Reference><Reference><Citation>Stan Development Team. RStan: the R interface to Stan. R package version 2.21.8. 2023. Available from: https://mc-stan.org
</Citation></Reference><Reference><Citation>Davies PJB, Russell CD, Morgan AR, Taori SK, Lindsay D, Ure R, et al. Increase of severe pulmonary infections in adults caused by M1(UK) Streptococcus pyogenes, Central Scotland, UK. Emerg Infect Dis. 2023;29(8):1638-42. 10.3201/eid2908.230569</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2908.230569</ArticleId><ArticleId IdType="pmc">PMC10370863</ArticleId><ArticleId IdType="pubmed">37343545</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdstock V, Twynam-Perkins J, Bradnock T, Dickson EM, Harvey-Wood K, Kalima P, et al. National case series of group A streptococcus pleural empyema in children: clinical and microbiological features. Lancet Infect Dis. 2023;23(2):154-6. 10.1016/S1473-3099(23)00008-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00008-7</ArticleId><ArticleId IdType="pubmed">36634683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynskey NN, Jauneikaite E, Li HK, Zhi X, Turner CE, Mosavie M, et al. Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. Lancet Infect Dis. 2019;19(11):1209-18. 10.1016/S1473-3099(19)30446-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(19)30446-3</ArticleId><ArticleId IdType="pmc">PMC6838661</ArticleId><ArticleId IdType="pubmed">31519541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rümke LW, de Gier B, Vestjens SMT, van der Ende A, van Sorge NM, Vlaminckx BJM, et al. Dominance of M1UK clade among Dutch M1 Streptococcus pyogenes. Lancet Infect Dis. 2020;20(5):539-40. 10.1016/S1473-3099(20)30278-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30278-4</ArticleId><ArticleId IdType="pubmed">32359464</ArticleId></ArticleIdList></Reference><Reference><Citation>Rümke LW, Davies MA, Vestjens SMT, van der Putten BCL, Bril-Keijzers WCM, van Houten MA, et al. Nationwide upsurge in invasive disease in the context of longitudinal surveillance of carriage and invasive Streptococcus pyogenes 2009-2023, the Netherlands: a molecular epidemiological study. J Clin Microbiol. 2024;e0076624.; Epub ahead of print. 10.1128/jcm.00766-24</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.00766-24</ArticleId><ArticleId IdType="pubmed">39194268</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MR, Keller N, Brouwer S, Jespersen MG, Cork AJ, Hayes AJ, et al. Detection of Streptococcus pyogenes M1UK in Australia and characterization of the mutation driving enhanced expression of superantigen SpeA. Nat Commun. 2023;14(1):1051. 10.1038/s41467-023-36717-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36717-4</ArticleId><ArticleId IdType="pmc">PMC9951164</ArticleId><ArticleId IdType="pubmed">36828918</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesen TB, Munkstrup C, Edslev SM, Baig S, Nielsen S, Funk T, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. Euro Surveill. 2023;28(26):2300291. 10.2807/1560-7917.ES.2023.28.26.2300291</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.26.2300291</ArticleId><ArticleId IdType="pmc">PMC10311951</ArticleId><ArticleId IdType="pubmed">37382884</ArticleId></ArticleIdList></Reference><Reference><Citation>Heins M, Korevaar J, Knottnerus B, Hooiveld M. Vaccine Coverage Dutch National Influenza Prevention Program 2021: brief monitor. In: Nivel, editor. 2022.</Citation></Reference><Reference><Citation>Frère J, Bidet P, Tapiéro B, Rallu F, Minodier P, Bonacorsi S, et al. Clinical and microbiological characteristics of invasive group A streptococcal infections before and after implementation of a universal varicella vaccine program. Clin Infect Dis. 2016;62(1):75-7. 10.1093/cid/civ793</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ793</ArticleId><ArticleId IdType="pubmed">26409062</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin O, Hazan G, Rokney A, Dayan R, Sagi O, Ben-Shimol S, et al. Invasive group A streptococcus infection in children in Southern Israel before and after the introduction of varicella vaccine. J Pediatric Infect Dis Soc. 2020;9(2):236-9. 10.1093/jpids/piz013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piz013</ArticleId><ArticleId IdType="pubmed">30927745</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera AL, Potts R, Huber VC, Chaussee MS. Influenza enhances host susceptibility to non-pulmonary invasive Streptococcus pyogenes infections. Virulence. 2023;14(1):2265063. 10.1080/21505594.2023.2265063</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2023.2265063</ArticleId><ArticleId IdType="pmc">PMC10566429</ArticleId><ArticleId IdType="pubmed">37772916</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>